Payer Policy

Aetna Prior Authorization Guide 2026: Clinical Policy Bulletins, Timelines & Appeals

Aetna CPB numbers, prior authorization submission steps, step therapy requirements, peer-to-peer contacts, and appeal strategies for specialty drugs in 2026.

RxCheckUp Clinical Team · 2026-05-11 · 12 min read

Aetna Prior Authorization: Who It Covers and How It Works

Aetna, now operating as a subsidiary of CVS Health, is one of the three largest commercial health insurers in the United States. Aetna's prior authorization program spans commercial fully-insured and self-insured (ASO) employer plans, Aetna Medicare Advantage, Aetna Medicaid managed care plans, and individual ACA marketplace products. The pharmacy benefit for most Aetna members is administered through CVS Caremark, which maintains its own prior authorization criteria and formulary separate from Aetna's medical benefit policies.

Aetna's clinical coverage policies are published as Clinical Policy Bulletins (CPBs). Each CPB covers one drug, device, or procedure and specifies the medical necessity criteria, required documentation, approved indications (including off-label uses Aetna will and will not cover), and coverage exclusions. CPBs are numbered (e.g., CPB 0327 for adalimumab, CPB 0648 for dupilumab) and are publicly accessible at aetna.com. These policy numbers are essential references: any appeal letter that cites the specific CPB and addresses its criteria by number is structurally stronger than a generic appeal.

Finding and Reading Aetna Clinical Policy Bulletins

CPBs are available at aetna.com under "Health Care Professionals > Clinical Policy Bulletins." The site allows keyword search by drug name or CPB number. Each CPB is organized into standard sections: Background (disease and drug overview), Medical Necessity Criteria (the gating criteria for approval), Experimental/Investigational uses (what Aetna explicitly excludes), Documentation Requirements, and References.

The "Medical Necessity" section is the operational core. It is written in conditional logic (e.g., "Aetna considers [drug] medically necessary for members who meet ALL of the following:"). Denials cite the specific unmet criterion. Appeals must address that criterion with the clinical evidence that demonstrates the patient meets it. Submitting a good clinical narrative that doesn't address the specific CPB language gives the Aetna reviewer grounds to uphold the denial without substantive clinical engagement.

CPBs are updated throughout the year — typically following new FDA approvals, NCCN guideline updates, or emerging clinical evidence. Always verify you are reviewing the current CPB version. A CPB that was revised between the initial PA submission and the appeal may have different criteria; if revised criteria are more favorable, cite the updated version explicitly in the appeal.

CVS Caremark Pharmacy Benefit PA vs Aetna Medical Benefit PA

The majority of Aetna members' specialty drug coverage flows through CVS Caremark for the pharmacy benefit and Aetna for the medical benefit. These are completely separate systems with different policies, portals, and decision timelines.

CVS Caremark pharmacy benefit PA covers drugs dispensed through retail, specialty pharmacy, or mail order. PA requests go through CVS Caremark's pharmacy portal or through the dispensing specialty pharmacy. Criteria are published in CVS Caremark's clinical PA criteria, which are distinct from Aetna CPBs even if they cover the same drugs. CVS Caremark has its own preferred biosimilar formulary (Hyrimoz and Cyltezo are commonly preferred for adalimumab) and its own site-of-care requirements.

Aetna medical benefit PA covers drugs administered in a healthcare setting — IV infusions, in-office injections, and similar. These are submitted through Aetna's medical management portal (availity.com or aetna.com/provider) against the applicable CPB. Routing a pharmacy-benefit drug to the Aetna medical benefit portal (or vice versa) is a common error that generates administrative denials and delays.

Step Therapy Requirements by Drug Class

Aetna's step therapy requirements are spelled out in each CPB's Medical Necessity Criteria. High-volume specialty drug classes with commonly required prior therapies:

✓ Rheumatoid arthritis biologics (TNF inhibitors, IL-6, JAK inhibitors): CPBs typically require documented failure of methotrexate at an adequate dose and duration (usually ≥3 months at therapeutic dose); JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) may require prior TNF inhibitor failure per FDA label warnings
✓ Psoriasis/PsA (IL-17, IL-23 inhibitors): plaque psoriasis CPBs often require phototherapy or methotrexate failure; PsA may require one DMARD trial; diagnosis documentation (PASI ≥10 or BSA ≥10% or DLQI ≥10 for plaque psoriasis) is consistently required
✓ Asthma biologics (dupilumab, mepolizumab, benralizumab, tezepelumab): CPBs require confirmation of severe uncontrolled asthma, baseline eosinophil count, and documentation that high-dose ICS with a LABA has been optimized before biologic initiation
✓ GLP-1s (semaglutide, tirzepatide): Aetna CPBs for obesity indications require BMI documentation, failed behavioral/lifestyle intervention, absence of pharmacotherapy contraindications; coverage for chronic weight management may not be included in all plan designs regardless of CPB criteria
✓ Oncology: Aetna generally aligns with NCCN Categories 1 and 2A; off-label use for Category 2B or 3 requires separate clinical justification and is often excluded by CPB language

Submitting a Prior Authorization to Aetna

Aetna accepts PA submissions through several channels. The Provider Portal at availity.com is the primary electronic submission channel and provides real-time acknowledgment and status tracking. Fax submissions are accepted but slower and carry higher documentation error rates.

✓ Medical benefit PA: submit via Availity → Aetna payer → Prior Authorization & Referrals; alternatively via aetna.com provider portal
✓ CVS Caremark pharmacy PA: submit via CVS Caremark portal or through the dispensing specialty pharmacy
✓ ePA: most major EHRs support electronic PA submission to Aetna for pharmacy benefit drugs via Surescripts network
✓ Decision timelines: Aetna must issue standard pre-service decisions within 15 calendar days for commercial non-urgent; expedited decisions within 72 hours; commercial urgent within 72 hours
✓ Aetna Medicare Advantage PA: must follow CMS timelines — standard 14 calendar days, expedited 72 hours; submitted through Aetna MA portal or by fax to the MA PA number on the member card
✓ PA status tracking: Availity portal provides live status; Aetna's IVR at 1-800-US-AETNA also provides status by reference number

Aetna Peer-to-Peer Review Process

Peer-to-peer (P2P) review is available for most Aetna medical benefit PA denials. The P2P is a physician-to-physician conversation between the prescriber and the Aetna medical director who issued the denial. Success rates for P2P reviews at Aetna are highest when the prescriber addresses the CPB criteria directly and presents new or additional clinical information not in the original submission.

The P2P request must generally be made within 30 calendar days of the denial. Request access by calling the number on the denial letter or through the Availity case management workflow. Aetna typically schedules P2P calls within 2-5 business days. The reviewing physician is generally specialty-matched, though this varies.

Preparation for a P2P with Aetna: pull the applicable CPB before the call, identify the exact criterion that was not met, prepare a 2-minute patient summary addressing that criterion specifically, have the chart open with lab values and prior therapy dates visible, and cite the specific clinical guideline that supports the request. P2P calls that open with "I disagree with the denial" are less effective than calls that open with "I have additional clinical documentation that addresses Criterion [X] of CPB [number]."

Appealing an Aetna Prior Authorization Denial

Aetna's commercial plan appeal process follows a two-level internal structure before external review. First-level appeals must be filed within 180 days of the denial notice for commercial plans. Aetna must respond within 30 days for pre-service standard decisions or 72 hours for expedited.

An effective Aetna appeal letter is structured around the CPB:

✓ Cite the CPB number and version date in the opening paragraph
✓ Quote the specific criterion cited in the denial and explain, with attached documentation, why the patient meets it
✓ Attach labs, imaging, and prior therapy records that directly correspond to the CPB documentation requirements
✓ Include at least two peer-reviewed citations supporting the clinical rationale — Aetna CPBs list the reference articles they consider authoritative; citing those same articles strengthens the appeal
✓ If the denial was "experimental/investigational," the appeal must show either (a) FDA approval for the specific indication, or (b) NCCN guideline or other compendium support for off-label use
✓ If ERISA applies (self-funded employer plan), include a statement invoking the member's ERISA appeal rights under 29 CFR 2560.503-1
✓ Include a request for external review if the internal appeal is denied — Aetna is required to provide external review information with the final denial notice for most plan types

Aetna Medicare Advantage and Medicaid PA

Aetna Medicare Advantage plans operate under the same CMS mandatory guidelines as all MA plans: 14-day standard PA decisions, 72-hour expedited decisions, and a mandatory four-level appeal process. The Aetna MA appeal process begins with an Organization Determination (Level 1), proceeds to a mandatory independent Reconsideration (Level 2, conducted by a CMS-contracted IRE — currently Maximus Federal Services for most MA plans), then ALJ hearing (Level 3) and MAC review (Level 4). Level 2 IRE review overturns Aetna MA denials at a significant rate for well-documented specialty drug cases.

Aetna Medicaid managed care plans operate under state contracts and follow state-specific PA and appeal timelines, which vary meaningfully across the states where Aetna manages Medicaid. Most Aetna Medicaid plans require prior treatment documentation and have a formulary with preferred drug list (PDL) requirements that differ from the commercial benefit.

High-Volume Aetna CPBs to Know

Aetna CPBs most frequently encountered in specialty pharmacy prior authorization workflows:

✓ CPB 0327 — Adalimumab (Humira) and adalimumab biosimilars: TNF inhibitor criteria for RA, PsA, Crohn's disease, plaque psoriasis, AS, uveitis; includes biosimilar substitution requirements
✓ CPB 0648 — Dupilumab (Dupixent): atopic dermatitis, asthma, CRSwNP, EoE, PRP criteria; eosinophil and IgE thresholds, ICS compliance documentation
✓ CPB 0827 — IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab): plaque psoriasis, PsA, AS criteria; prior DMARD/phototherapy requirements
✓ CPB 0951 — GLP-1 receptor agonists (semaglutide, tirzepatide) for obesity/weight management: BMI criteria, comorbidity documentation, failed lifestyle intervention
✓ CPB 0752 — Anti-PD-1/PD-L1 checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab): oncology NCCN alignment; biomarker requirements (PD-L1 TPS, MSI-H, TMB)
✓ CPB 0876 — Anti-CD20 agents (ocrelizumab, ofatumumab, rituximab): MS and oncology indications; neurologist documentation requirements for MS indications
✓ CPB 0698 — CGRP inhibitors (erenumab, fremanezumab, galcanezumab, eptinezumab): chronic migraine criteria; failed prior prophylactics documentation